777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Financial Results, Press Release
Regeneron Pharmaceuticals Reports $127 Million IPR&D Charge for Q2 2026
2026 Annual Meeting Results - Directors Elected at Regeneron Pharmaceuticals
Reports First Quarter 2026 Financial and Operating Results
Annual Report to Security Holders
Earnings Release
Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Investor Presentation
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Annual Report of Proxy Voting Record
Notice of Proposed Sale of Securities
Quarterly Holdings Report for Institutional Managers
Submission Upload
Correspondence